Interventional technology developer Cordis Endovascular has released data from four international clinical studies for its Cypher sirolimus-eluting coronary stent at the 2004 Paris Course on Revascularization (PCR) this week in Paris.
The stent is designed to treat higher-risk and challenging blockages in coronary arteries, including small-vessel blockages, chronic total occlusions, in-stent restenosis, and multivessel disease, according to the Warren, NJ-based firm.
The studies -- Svelte, for small coronary arteries; Tropical for in-stent restenosis; Sicto, for chronic total occlusions; and Arts II, for sirolimus-eluting stents versus coronary artery bypass graft (CABG) in the treatment of multivessel disease -- showed that the Cypher stent significantly reduced recurrent blockage of arteries from compared with results seen with conventional bare-metal stents, Cordis said.
By AuntMinnie.com staff writersMay 26, 2004
Related Reading
Cordis recalls instructions for biliary stent, May 10, 2004
Cordis stent gets FDA panel recommendation, April 22, 2004
Cordis stent gets CE OK, April 8, 2004
Guidant, Johnson & Johnson ink stent deal, February 27, 2004
Cordis stent gets FDA OK, September 5, 2003
Copyright © 2004 AuntMinnie.com
